Solid tumours

Initial data from an ongoing Phase I/II study of HPK1 inhibitor NDI-101150 show clinical benefit in three patients with solid tumours, including one complete response in a patient with renal cell carcinoma. Two patients with pancreatic cancer and renal cell carcinoma, respectively, exhibited prolonged (> six months) stable disease. NDI-101150 demonstrated an acceptable safety profile […]

Kura Oncology’s FIT-001 Phase I dose-escalation trial of KO-2806, a farnesyl transferase inhibitor (FTI) for the treatment of advanced solid tumours, has commenced with the dosing of the first patient. FIT-001 is a first-in-human, multicentre, open-label study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of KO-2806 when administered as monotherapy and […]

Iksuda Therapeutics has dosed the first patient in a Phase I trial of antibody drug conjugate (ADC) IKS014 in patients with advanced solid tumours that express HER2. This follows positive data from Phase I clinical trials through Fosun Pharma, which is now progressing FS-1502 (IKS014) through Phase II and Phase III trials in China. The […]

CARsgen has published evidence of over seven years of disease-free survival in advanced hepatocellular carcinoma (HCC) following treatment with its CAR-GPC3 T cell therapy. Hepatocellular carcinoma is one of the most common malignant tumours, with approximately 780,000 annual incidence cases globally. Recurrence and metastasis are common. For HCC patients with concurrent inferior vena cava tumour […]

Aulos Bioscience has revealed new safety and efficacy data from the Phase I dose escalation portion of its Phase I/II clinical trial of AU-007 in patients with unresectable locally advanced or metastatic solid tumour cancers. The data will be presented at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting, being held in San […]

Leucid Bio has been granted clinical trial authorisation by the UK Medicines and Healthcare products Regulatory Agency (MHRA) to initiate a Phase I/II clinical trial evaluating autologous NKG2D-targeted CAR-T cell therapy, LEU011, in patients with relapsed or refractory solid tumours. The open-label, single patient cohort ascending dose design aims to rapidly identify the maximum tolerated […]

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  The news headlines this week reflect the level of interest in cell & gene therapies (CGT) in the sector, particularly CAR-T, but also […]

Research partners in the UK are progressing their orally available small molecule cancer immunotherapy drug into clinical development as a treatment for advanced solid tumours. Sosei Group and Cancer Research UK announced that the first patient has been dosed in a Phase I/IIa clinical trial evaluating Sosei Heptares’ immunotherapy drug HTL0039732. HTL0039732 works by blocking […]

News round-up for by DDW Digital Content Editor Diana Spencer. The news headlines this week reflect the level of interest in cell & gene therapies (CGT) in the sector, particularly CAR-T, but also the importance of research collaborations to bring these therapies to patients. Traditionally successful in treating blood cancers, it is positive to see […]

GenScript Biotech and T-MAXIMUM Biotech have formed a strategic collaboration to develop T-MAXIMUM’s CAR-T cell therapy using GenScript’s CRISPR nucleic acid reagents. GenScript will provide various CRISPR reagents to support the development of the universal CAR-T products from discovery to commercialisation. T-MAXIMUM Biotech hopes to progress multiple products to the Phase II clinical research stage […]

Astellas Pharma will invest $50 million into Poseida Therapeutics to secure the rights to the company’s cancer CAR-T cell therapy for solid tumours, which is currently in Phase I trials. The total $50 million will include $25 million to acquire 8,333,333 shares of common stock of Poseida and a one-time $25 million payment for first […]

Investigators at the Icahn School of Medicine at Mount Sinai have designed an RNA-based strategy to activate dendritic cells that eradicated tumours and prevented their recurrence in mouse models of melanoma. The findings, which suggest that the approach has the potential to be effective against tumours that have already spread to other parts of the […]

Immuno-oncology company Crescendo Biologics has revealed plans to augment the ongoing Phase Ib clinical trial of CB307 through the addition of a new pembrolizumab (anti-PD-1) combination expansion cohort. Additional financing of $32 million has been secured with the support of all major existing shareholders, including Sofinnova Partners, Andera Partners, IP Group BioNTech, Takeda and Quan […]

Lantern Pharma, an AI company developing targeted and transformative cancer therapies, has received clearance from the US Food and Drug Administration (FDA) for the investigational new drug (IND) application for LP-184, which is being developed for multiple advanced solid tumours and central nervous system (CNS) cancers.   The first-in-human Phase Ia trial for LP-184 is anticipated […]

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  With National Cancer Research Month coming to an end in May and the American Society of Clinical Oncology Annual Meeting currently taking place in Chicago […]

News round-up for 29 May – 2 June by DDW Digital Content Editor Diana Spencer. With National Cancer Research Month coming to an end and the American Society of Clinical Oncology Annual Meeting currently taking place in Chicago (2-6 June), it’s been another busy week for cancer drug development news. The top stories: Janssen seeks […]